Medicine (Austin & Northern Health) - Research Publications

Permanent URI for this collection

Search Results

Now showing 1 - 10 of 10
  • Item
    No Preview Available
    De novo mutations in ATP1A3 cause alternating hemiplegia of childhood
    Heinzen, EL ; Swoboda, KJ ; Hitomi, Y ; Gurrieri, F ; Nicole, S ; de Vries, B ; Tiziano, FD ; Fontaine, B ; Walley, NM ; Heavin, S ; Panagiotakaki, E ; Fiori, S ; Abiusi, E ; Di Pietro, L ; Sweney, MT ; Newcomb, TM ; Viollet, L ; Huff, C ; Jorde, LB ; Reyna, SP ; Murphy, KJ ; Shianna, KV ; Gumbs, CE ; Little, L ; Silver, K ; Ptacek, LJ ; Haan, J ; Ferrari, MD ; Bye, AM ; Herkes, GK ; Whitelaw, CM ; Webb, D ; Lynch, BJ ; Uldall, P ; King, MD ; Scheffer, IE ; Neri, G ; Arzimanoglou, A ; van den Maagdenberg, AMJM ; Sisodiya, SM ; Mikati, MA ; Goldstein, DB (NATURE PUBLISHING GROUP, 2012-09)
    Alternating hemiplegia of childhood (AHC) is a rare, severe neurodevelopmental syndrome characterized by recurrent hemiplegic episodes and distinct neurological manifestations. AHC is usually a sporadic disorder and has unknown etiology. We used exome sequencing of seven patients with AHC and their unaffected parents to identify de novo nonsynonymous mutations in ATP1A3 in all seven individuals. In a subsequent sequence analysis of ATP1A3 in 98 other patients with AHC, we found that ATP1A3 mutations were likely to be responsible for at least 74% of the cases; we also identified one inherited mutation in a case of familial AHC. Notably, most AHC cases are caused by one of seven recurrent ATP1A3 mutations, one of which was observed in 36 patients. Unlike ATP1A3 mutations that cause rapid-onset dystonia-parkinsonism, AHC-causing mutations in this gene caused consistent reductions in ATPase activity without affecting the level of protein expression. This work identifies de novo ATP1A3 mutations as the primary cause of AHC and offers insight into disease pathophysiology by expanding the spectrum of phenotypes associated with mutations in ATP1A3.
  • Item
    Thumbnail Image
    The Role of Seizure-Related SEZ6 as a Susceptibility Gene in Febrile Seizures
    Mulley, JC ; Iona, X ; Hodgson, B ; Heron, SE ; Berkovic, SF ; Scheffer, IE ; Dibbens, LM (HINDAWI LTD, 2011)
    Sixty cases of febrile seizures from a Chinese cohort had previously been reported with a strong association between variants in the seizure-related (SEZ) 6 gene and febrile seizures. They found a striking lack of genetic variation in their controls. We found genetic variation in SEZ6 at similar levels at the same DNA sequence positions in our 94 febrile seizure cases as in our 96 unaffected controls. Two of our febrile seizure cases carried rare variants predicted to have damaging consequences. Combined with some of the variants from the Chinese cohort, these data are compatible with a role for SEZ6 as a susceptibility gene for febrile seizures. However, the polygenic determinants underlying most cases of febrile seizures with complex inheritance remain to be determined.
  • Item
    Thumbnail Image
    Dravet syndrome as epileptic encephalopathy: evidence from long-term course and neuropathology
    Catarino, CB ; Liu, JYW ; Liagkouras, I ; Gibbons, VS ; Labrum, RW ; Ellis, R ; Woodward, C ; Davis, MB ; Smith, SJ ; Cross, JH ; Appleton, RE ; Yendle, SC ; McMahon, JM ; Bellows, ST ; Jacques, TS ; Zuberi, SM ; Koepp, MJ ; Martinian, L ; Scheffer, IE ; Thom, M ; Sisodiya, SM (OXFORD UNIV PRESS, 2011-10)
    Dravet syndrome is an epilepsy syndrome of infantile onset, frequently caused by SCN1A mutations or deletions. Its prevalence, long-term evolution in adults and neuropathology are not well known. We identified a series of 22 adult patients, including three adult post-mortem cases with Dravet syndrome. For all patients, we reviewed the clinical history, seizure types and frequency, antiepileptic drugs, cognitive, social and functional outcome and results of investigations. A systematic neuropathology study was performed, with post-mortem material from three adult cases with Dravet syndrome, in comparison with controls and a range of relevant paediatric tissue. Twenty-two adults with Dravet syndrome, 10 female, were included, median age 39 years (range 20-66). SCN1A structural variation was found in 60% of the adult Dravet patients tested, including one post-mortem case with DNA extracted from brain tissue. Novel mutations were described for 11 adult patients; one patient had three SCN1A mutations. Features of Dravet syndrome in adulthood include multiple seizure types despite polytherapy, and age-dependent evolution in seizure semiology and electroencephalographic pattern. Fever sensitivity persisted through adulthood in 11 cases. Neurological decline occurred in adulthood with cognitive and motor deterioration. Dysphagia may develop in or after the fourth decade of life, leading to significant morbidity, or death. The correct diagnosis at an older age made an impact at several levels. Treatment changes improved seizure control even after years of drug resistance in all three cases with sufficient follow-up after drug changes were instituted; better control led to significant improvement in cognitive performance and quality of life in adulthood in two cases. There was no histopathological hallmark feature of Dravet syndrome in this series. Strikingly, there was remarkable preservation of neurons and interneurons in the neocortex and hippocampi of Dravet adult post-mortem cases. Our study provides evidence that Dravet syndrome is at least in part an epileptic encephalopathy.
  • Item
    No Preview Available
    PRRT2 phenotypic spectrum includes sporadic and fever-related infantile seizures
    Scheffer, IE ; Grinton, BE ; Heron, SE ; Kivity, S ; Afawi, Z ; Iona, X ; Goldberg-Stern, H ; Kinali, M ; Andrews, I ; Guerrini, R ; Marini, C ; Sadleir, LG ; Berkovic, SF ; Dibbens, LM (LIPPINCOTT WILLIAMS & WILKINS, 2012-11)
    OBJECTIVE: Benign familial infantile epilepsy (BFIE) is an autosomal dominant epilepsy syndrome characterized by afebrile seizures beginning at about 6 months of age. Mutations in PRRT2, encoding the proline-rich transmembrane protein 2 gene, have recently been identified in the majority of families with BFIE and the associated syndrome of infantile convulsions and choreoathetosis (ICCA). We asked whether the phenotypic spectrum of PRRT2 was broader than initially recognized by studying patients with sporadic benign infantile seizures and non-BFIE familial infantile seizures for PRRT2 mutations. METHODS: Forty-four probands with infantile-onset seizures, infantile convulsions with mild gastroenteritis, and benign neonatal seizures underwent detailed phenotyping and PRRT2 sequencing. The familial segregation of mutations identified in probands was studied. RESULTS: The PRRT2 mutation c.649-650insC (p.R217fsX224) was identified in 11 probands. Nine probands had a family history of BFIE or ICCA. Two probands had no family history of infantile seizures or paroxysmal kinesigenic dyskinesia and had de novo PRRT2 mutations. Febrile seizures with or without afebrile seizures were observed in 2 families with PRRT2 mutations. CONCLUSIONS: PRRT2 mutations are present in >80% of BFIE and >90% ICCA families, but are not a common cause of other forms of infantile epilepsy. De novo mutations of PRRT2 can cause sporadic benign infantile seizures. Seizures with fever may occur in BFIE such that it may be difficult to distinguish BFIE from febrile seizures and febrile seizures plus in small families.
  • Item
    No Preview Available
    PRRT2 Mutations Cause Benign Familial Infantile Epilepsy and Infantile Convulsions with Choreoathetosis Syndrome
    Heron, SE ; Grinton, BE ; Kivity, S ; Afawi, Z ; Zuberi, SM ; Hughes, JN ; Pridmore, C ; Hodgson, BL ; Iona, X ; Sadleir, LG ; Pelekanos, J ; Herlenius, E ; Goldberg-Stern, H ; Bassan, H ; Haan, E ; Korczyn, AD ; Gardner, AE ; Corbett, MA ; Gecz, J ; Thomas, PQ ; Mulley, JC ; Berkovic, SF ; Scheffer, IE ; Dibbens, LM (CELL PRESS, 2012-01-13)
    Benign familial infantile epilepsy (BFIE) is a self-limited seizure disorder that occurs in infancy and has autosomal-dominant inheritance. We have identified heterozygous mutations in PRRT2, which encodes proline-rich transmembrane protein 2, in 14 of 17 families (82%) affected by BFIE, indicating that PRRT2 mutations are the most frequent cause of this disorder. We also report PRRT2 mutations in five of six (83%) families affected by infantile convulsions and choreoathetosis (ICCA) syndrome, a familial syndrome in which infantile seizures and an adolescent-onset movement disorder, paroxysmal kinesigenic choreoathetosis (PKC), co-occur. These findings show that mutations in PRRT2 cause both epilepsy and a movement disorder. Furthermore, PRRT2 mutations elicit pleiotropy in terms of both age of expression (infancy versus later childhood) and anatomical substrate (cortex versus basal ganglia).
  • Item
    No Preview Available
    Early onset absence epilepsy: 1 in 10 cases is caused by GLUT1 deficiency
    Arsov, T ; Mullen, SA ; Damiano, JA ; Lawrence, KM ; Huh, LL ; Nolan, M ; Young, H ; Thouin, A ; Dahl, H-HM ; Berkovic, SF ; Crompton, DE ; Sadleir, LG ; Scheffer, IE (WILEY-BLACKWELL, 2012-12)
    Glucose transporter 1 (GLUT1) deficiency caused by mutations of SLC2A1 is an increasingly recognized cause of genetic generalized epilepsy. We previously reported that >10% (4 of 34) of a cohort with early onset absence epilepsy (EOAE) had GLUT1 deficiency. This study uses a new cohort of 55 patients with EOAE to confirm that finding. Patients with typical absence seizures beginning before 4 years of age were screened for solute carrier family 2 (facilitated glucose transporter), member 1 (SLC2A1) mutations or deletions. All had generalized spike-waves on electroencephalography (EEG). Those with tonic and/or atonic seizures were excluded. Mutations were found in 7 (13%) of 55 cases, including five missense mutations, an in-frame deletion leading to loss of a single amino acid, and a deletion spanning two exons. Over both studies, 11 (12%) of 89 probands with EOAE have GLUT1 deficiency. Given the major treatment and genetic counseling implications, this study confirms that SLC2A1 mutational analysis should be strongly considered in EOAE.
  • Item
    No Preview Available
    Genome-wide association analysis of genetic generalized epilepsies implicates susceptibility loci at 1q43, 2p16.1, 2q22.3 and 17q21.32
    Steffens, M ; Leu, C ; Ruppert, A-K ; Zara, F ; Striano, P ; Robbiano, A ; Capovilla, G ; Tinuper, P ; Gambardella, A ; Bianchi, A ; La Neve, A ; Crichiutti, G ; de Kovel, CGF ; Trenite, DK-N ; de Haan, G-J ; Lindhout, D ; Gaus, V ; Schmitz, B ; Janz, D ; Weber, YG ; Becker, F ; Lerche, H ; Steinhoff, BJ ; Kleefuss-Lie, AA ; Kunz, WS ; Surges, R ; Elger, CE ; Muhle, H ; von Spiczak, S ; Ostertag, P ; Helbig, I ; Stephani, U ; Moller, RS ; Hjalgrim, H ; Dibbens, LM ; Bellows, S ; Oliver, K ; Mullen, S ; Scheffer, IE ; Berkovic, SF ; Everett, KV ; Gardiner, MR ; Marini, C ; Guerrini, R ; Lehesjoki, A-E ; Siren, A ; Guipponi, M ; Malafosse, A ; Thomas, P ; Nabbout, R ; Baulac, S ; Leguern, E ; Guerrero, R ; Serratosa, JM ; Reif, PS ; Rosenow, F ; Moerzinger, M ; Feucht, M ; Zimprich, F ; Kapser, C ; Schankin, CJ ; Suls, A ; Smets, K ; De Jonghe, P ; Jordanova, A ; Caglayan, H ; Yapici, Z ; Yalcin, DA ; Baykan, B ; Bebek, N ; Ozbek, U ; Gieger, C ; Wichmann, H-E ; Balschun, T ; Ellinghaus, D ; Franke, A ; Meesters, C ; Becker, T ; Wienker, TF ; Hempelmann, A ; Schulz, H ; Rueschendorf, F ; Leber, M ; Pauck, SM ; Trucks, H ; Toliat, MR ; Nuernberg, P ; Avanzini, G ; Koeleman, BPC ; Sander, T (OXFORD UNIV PRESS, 2012-12-15)
    Genetic generalized epilepsies (GGEs) have a lifetime prevalence of 0.3% and account for 20-30% of all epilepsies. Despite their high heritability of 80%, the genetic factors predisposing to GGEs remain elusive. To identify susceptibility variants shared across common GGE syndromes, we carried out a two-stage genome-wide association study (GWAS) including 3020 patients with GGEs and 3954 controls of European ancestry. To dissect out syndrome-related variants, we also explored two distinct GGE subgroups comprising 1434 patients with genetic absence epilepsies (GAEs) and 1134 patients with juvenile myoclonic epilepsy (JME). Joint Stage-1 and 2 analyses revealed genome-wide significant associations for GGEs at 2p16.1 (rs13026414, P(meta) = 2.5 × 10(-9), OR[T] = 0.81) and 17q21.32 (rs72823592, P(meta) = 9.3 × 10(-9), OR[A] = 0.77). The search for syndrome-related susceptibility alleles identified significant associations for GAEs at 2q22.3 (rs10496964, P(meta) = 9.1 × 10(-9), OR[T] = 0.68) and at 1q43 for JME (rs12059546, P(meta) = 4.1 × 10(-8), OR[G] = 1.42). Suggestive evidence for an association with GGEs was found in the region 2q24.3 (rs11890028, P(meta) = 4.0 × 10(-6)) nearby the SCN1A gene, which is currently the gene with the largest number of known epilepsy-related mutations. The associated regions harbor high-ranking candidate genes: CHRM3 at 1q43, VRK2 at 2p16.1, ZEB2 at 2q22.3, SCN1A at 2q24.3 and PNPO at 17q21.32. Further replication efforts are necessary to elucidate whether these positional candidate genes contribute to the heritability of the common GGE syndromes.
  • Item
    No Preview Available
    In vivo loss of slow potassium channel activity in individuals with benign familial neonatal epilepsy in remission
    Tomlinson, SE ; Bostock, H ; Grinton, B ; Hanna, MG ; Kullmann, DM ; Kiernan, MC ; Scheffer, IE ; Berkovic, SF ; Burke, D (OXFORD UNIV PRESS, 2012-10)
    Benign familial neonatal epilepsy is a neuronal channelopathy most commonly caused by mutations in KCNQ2, which encodes the K(v)7.2 subunit of the slow K(+) channel. K(v)7.2 is expressed in both central and peripheral nervous systems. Seizures occur in the neonatal period, often in clusters within the first few days of life, and usually remit by 12 months of age. The mechanism of involvement of K(v)7.2 mutations in the process of seizure generation has not been established in vivo. In peripheral axons, K(v)7.2 contributes to the nodal slow K(+) current. The present study aimed to determine whether axonal excitability studies could detect changes in peripheral nerve function related to dysfunction or loss of slow potassium channel activity. Nerve excitability studies were performed on eight adults with KCNQ2 mutations and a history of benign familial neonatal epilepsy, now in remission. Studies detected distinctive changes in peripheral nerve, indicating a reduction in slow K(+) current. Specifically, accommodation to long-lasting depolarizing currents was reduced in mutation carriers by 24% compared with normal controls, and the threshold undershoot after 100 ms depolarizing currents was reduced by 22%. Additional changes in excitability included a reduction in the relative refractory period, an increase in superexcitability and a tendency towards reduced sub-excitability. Modelling of the nerve excitability changes suggested that peripheral nerve hyperexcitability may have been ameliorated by upregulation of other potassium channels. We conclude that subclinical dysfunction of K(v)7.2 in peripheral axons can be reliably detected non-invasively in adulthood. Related alterations in neuronal excitability may contribute to epilepsy associated with KCNQ2 mutations.
  • Item
    Thumbnail Image
    Epi4K: Gene discovery in 4,000 genomes
    Berkovic, S ; Cossette, P ; Delanty, N ; Dlugos, D ; Eichler, E ; Epstein, M ; Glauser, T ; Goldstein, D ; Heinzen, E ; Johnson, MR ; Kuzniecky, R ; Lowenstein, D ; Marson, T ; Mefford, H ; O'Brien, T ; Ottman, R ; Poduri, A ; Scheffer, I ; Sherr, E ; Shianna, K (WILEY, 2012-08)
    A major challenge in epilepsy research is to unravel the complex genetic mechanisms underlying both common and rare forms of epilepsy, as well as the genetic determinants of response to treatment. To accelerate progress in this area, the National Institute of Neurological Disorders and Stroke (NINDS) recently offered funding for the creation of a "Center without Walls" to focus on the genetics of human epilepsy. This article describes Epi4K, the collaborative study supported through this grant mechanism and having the aim of analyzing the genomes of a minimum 4,000 subjects with highly selected and well-characterized epilepsy.
  • Item
    No Preview Available
    Familial focal epilepsy with variable foci mapped to chromosome 22q12: Expansion of the phenotypic spectrum
    Klein, KM ; O'Brien, TJ ; Praveen, K ; Heron, SE ; Mulley, JC ; Foote, S ; Berkovic, SF ; Scheffer, IE (WILEY-BLACKWELL, 2012-08)
    We aimed to refine the phenotypic spectrum and map the causative gene in two families with familial focal epilepsy with variable foci (FFEVF). A new five-generation Australian FFEVF family (A) underwent electroclinical phenotyping, and the original four-generation Australian FFEVF family (B) (Ann Neurol, 44, 1998, 890) was re-analyzed, including new affected individuals. Mapping studies examined segregation at the chromosome 22q12 FFEVF region. In family B, the original whole genome microsatellite data was reviewed. Five subjects in family A and 10 in family B had FFEVF with predominantly awake attacks and active EEG studies with a different phenotypic picture from other families. In family B, reanalysis excluded the tentative 2q locus reported. Both families mapped to chromosome 22q12. Our results confirm chromosome 22q12 as the solitary locus for FFEVF. Both families show a subtly different phenotype to other published families extending the clinical spectrum of FFEVF.